Spero Therapeutics, Inc. (SPRO)
1.20
-0.02
(-1.64%)
USD |
NASDAQ |
Sep 01, 16:00
1.20
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Research and Development Expense (Annual) : 38.47M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 38.47M |
| December 31, 2024 | 96.76M |
| December 31, 2023 | 51.07M |
| December 31, 2022 | 46.05M |
| December 31, 2021 | 63.41M |
| December 31, 2020 | 66.24M |
| Date | Value |
|---|---|
| December 31, 2019 | 64.62M |
| December 31, 2018 | 33.88M |
| December 31, 2017 | 32.87M |
| December 31, 2016 | 26.33M |
| December 31, 2015 | 11.12M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Inovio Pharmaceuticals, Inc. | 52.79M |
| Fortress Biotech, Inc. | 11.90M |
| Kura Oncology, Inc. | 251.07M |
| Legend Biotech Corp. | 415.80M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |